The PNPLA3 risk variant, but not the TM6SF2 genotype, was an independent risk factor for developing hepatic fibrosis among patients with NAFLD (HR 1.17, 95% CI 1.04–1.32, P = 0.010). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.